drugset / Trial / NCT05643677
Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study explores the efficacy and safety of fruquintinib combined with irinotecan in the second-line treatment of patients with advanced gastric cancer, aiming to bring more second-line treatment options for patients with advanced gastric cancer.
Timeline
- Start
- 2022-12
- Primary completion
- 2024-11
- Completion
- 2025-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 4 mg | Oral |
| Subject | Irinotecan | Small molecule | 100 mg/m2 | Intravenous |